Clinical Trials Logo

Metastatic Cervical Cancer clinical trials

View clinical trials related to Metastatic Cervical Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05614453 Withdrawn - Clinical trials for Metastatic Cervical Cancer

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

ITTACC
Start date: June 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effect of the combination treatment of sitravatinib with tislelizumab in patients with Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy. The main question it aims to answer is the percentage of people in the study who have a partial or complete response to the treatment. Participants will receive treatment under the care of their treating physician and will be reviewed regularly.

NCT ID: NCT04943627 Withdrawn - Advanced Cancer Clinical Trials

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Start date: August 2, 2021
Phase: Phase 3
Study type: Interventional

This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with recurrent, persistent, or metastatic cervical cancer who have progressed after receiving platinum based chemotherapy.